FDA rejects Gilead’s next big HIV drug over glass vial issues

Gilead on Tuesday received a rejection letter for its latest potential first-in-class HIV drug, as the company said the FDA cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with its proposed container vial.

Regulators previously slapped a clinical hold on 10 trials studying injectable versions...

Click to view original post